The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 04, 2018

Filed:

Nov. 30, 2012
Applicant:

Sarepta Therapeutics, Inc., Bothell, WA (US);

Inventors:

Peter Linsley, Seattle, WA (US);

Brian James Leppert, Kenmore, WA (US);

Gunnar J. Hanson, Bothell, WA (US);

Assignee:

SAREPTA THERAPEUTICS, INC., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); C07H 21/04 (2006.01); C12Q 1/6883 (2018.01); C12N 15/11 (2006.01); C07F 9/6558 (2006.01); C07F 9/6561 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); C07F 9/65583 (2013.01); C07F 9/65616 (2013.01); C07H 21/04 (2013.01); C12N 15/111 (2013.01); C12Q 1/6883 (2013.01); C12N 2310/323 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/3233 (2013.01); C12N 2320/34 (2013.01); C12Q 2600/156 (2013.01);
Abstract

The invention provides for a method for selectively reducing the expression of a mutant mRNA and/or protein having an expanded nucleotide repeat relative to a wild-type mRNA, comprising contacting a cell with an antisense oligonucleotide of sufficient length and complementarity to the expanded nucleotide repeat. More particularly it relates to selectively reducing the expression of mutant Huntington protein associated with Huntington's disease. The antisense oligonucleotide comprising either a nucleotide or a repeated three nucleotide sequence as defined in the claims.


Find Patent Forward Citations

Loading…